Key result
Adenosine A2A receptor agonist infusion significantly improved recovery of LAD zone thickening compared to control in both 4-cycle (91% vs 56%) and 10-cycle (65% vs 8%) occlusion models (P<0.05).
Why the study?
Does a low, nonvasodilating dose of an adenosine A2A receptor agonist improve myocardial functional recovery in a canine model of myocardial stunning?
Does a low, nonvasodilating dose of an adenosine A2A receptor agonist improve myocardial functional recovery in a canine model of myocardial stunning?
p-value: p=<0.05
Low-dose adenosine A2A receptor agonists significantly attenuate postischemic stunning and improve functional recovery in a canine model of transient ischemia.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for A2A agonists in stunning; leaves open clinical translation.
Glover et al. (2007) studied myocardial stunning produced by multiple episodes of transient ischemia (n=24). adenosine A(2A) receptor agonist (ATL-193 or ATL-146e) vs. control was evaluated on recovery of LAD zone thickening after 180 min of reperfusion (p=<0.05). Adenosine A2A receptor agonist infusion significantly improved recovery of LAD zone thickening compared to control in both 4-cycle (91% vs 56%) and 10-cycle (65% vs 8%) occlusion models (P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: